课题基金 / 基金详情

Disordered Regulation of Wnt/beta-catenin Signaling in MPNST Development and Maintenance

Disordered Regulation of Wnt/beta-catenin Signaling in MPNST Development and Maintenance
MPNST 发育和维持中 Wnt/β-catenin 信号传导的紊乱调节
批准号:
8814072
负责人:
DAVID ANDREW LARGAESPADA
金额:
$49.03万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-08-15 至 2019-06-30

项目摘要

项目成果

DAVID ANDREW LARGAESPADA的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): We carried out two large screens to identify genes driving MPNST formation or maintenance: 1) An shRNA screen in human MPNST cell lines, and 2) a Sleeping Beauty (SB) transposon- based insertional mutagenesis screen in a mouse model of MPNST. Both research approaches identified Wnt/β catenin-regulated pathways as critical mediators of MPNST maintenance. Preliminary data confirms that the Wnt/β catenin pathway is required for MPNST maintenance and can be targeted using small molecules. Remarkably, we identified multiple mechanisms of activation of β β catenin that operate in MPNST. Our proposal focuses on these. Aim 1 is based on our data demonstrating that genetic or pharmacological activation of the β catenin destruction complex reduce β catenin levels, reduce target gene expression, and inhibit cell survival and proliferation in MPNST. Aim 2 is based on data showing that some MPNSTs ectopically express a Wnt/β catenin activator R-spondin 2 (RSPO2) due to transcript fusion with the upstream EIF3E gene, a mechanism we recently identified in human colorectal cancer. Aim 3 is based on data revealing that the β catenin target gene PITX2 plays a critical role in MPNST cell survival. Our goals are two-fold: to define the molecular landscape of β catenin de-regulation in MPNST, and perform a thorough pre-clinical evaluation of critical targets for intervention in the Wnt/β catenin pathway in MPNST, setting the stage for effective clinical testing in human patients. The Co-PIs have established a successful collaborative relationship built on complementary skills and resources. Abundant and orthogonal preliminary data support the basic hypothesis of this proposal.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Integrated Immune Engineering for Poor Prognosis Cancers
  • 批准号:
    10700921
  • 项目类别:
  • 资助金额:
    $186.91万
  • 财政年份:
    2021
  • 负责人:
    DAVID ANDREW LARGAESPADA
  • 依托单位:
Integrated Immune Engineering for Poor Prognosis Cancers
  • 批准号:
    10270392
  • 项目类别:
  • 资助金额:
    $192.1万
  • 财政年份:
    2021
  • 负责人:
    DAVID ANDREW LARGAESPADA
  • 依托单位:
Uncovering treatment targets for peripheral nerve sheath tumor progression in NF1
  • 批准号:
    10439480
  • 项目类别:
  • 资助金额:
    $57.74万
  • 财政年份:
    2020
  • 负责人:
    DAVID ANDREW LARGAESPADA
  • 依托单位:
Uncovering treatment targets for peripheral nerve sheath tumor progression in NF1
  • 批准号:
    10653687
  • 项目类别:
  • 资助金额:
    $57.18万
  • 财政年份:
    2020
  • 负责人:
    DAVID ANDREW LARGAESPADA
  • 依托单位:
海外基金